Articles

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

Quality of Life Research Center, Department of Haematology, Odense University Hospital, Odense, Denmark
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam, the Netherlands
HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gotheborg, Sweden
Department of Haematology, Rigshospitalet, Copenhagen, Denmark
Department of Haematology, Maastricht University Medical Center, Maastricht, the Netherlands
Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands
HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Department of Haematology and Wallenberg Center for Molecular Medicine, Skåne University Hospital, Lund University, Lund, Sweden
Department of Internal Medicine, Martini Ziekenhuis, Groningen, the Netherlands
Department of Internal Medicine, Tergooi Ziekenhuis, Hilversum, the Netherlands
Department of Internal Medicine, Isala, Zwolle, the Netherlands
Department of Internal Medicine, Division of Hematology, Vejle Hospital, Vejle, Denmark
Department of Internal Medicine, Meander Medisch Centrum, Amersfoort, the Netherlands
Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, the Netherlands
Department of Oncology, Haematology and Palliative Care, Førde Central Hospital, Førde, Norway
Department of Internal Medicine, Reinier de Graaf Ziekenhuis, Delft, the Netherlands
Department of Internal Medicine, Northwest Clinics, Alkmaar, the Netherlands
Department of Internal Medicine, Maasstad Ziekenhuis, Rotterdam, the Netherlands
Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands
Department of Haematology, Stavanger University Hospital, Stavanger, Norway
Department of Internal Medicine, Zaans Medisch Centrum, Zaandam, the Netherlands
Department of Internal Medicine, Tweesteden Ziekenhuis, Tilburg, the Netherlands
Department of Haematology, Rigshospitalet, Copenhagen, Denmark
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands
Department of Haematology, Erasmus Medical Center Cancer Center, Rotterdam, the Netherlands
Department of Haematology, St Olavs Hospital and Norwegian University of Science and Technology, Trondheim, Norway
Quality of Life Research Center, Department of Haematology, Odense University Hospital, Odense, Denmark
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands
Vol. 105 No. 6 (2020): June, 2020 https://doi.org/10.3324/haematol.2019.222299